Page 3 - Pneumococcal News Today

Tergene Biotech gets recommendation from CDSCO subject expert committee for pneumococcal 15-valent vaccine

Positive pivotal top-line data demonstrates 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, can likely help protect against all 20 vaccine serotypes in three-dose series

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the

NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) announced Friday positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) evaluating its 20-valent pneumococcal conjugate

France: Implementing a 13-valent pneumococcal conjugate vaccine (PCV13) in the general pediatric population may reduce the incidence of acute chest syndrome (ACS) in children with sickle-cell disease...

KENILWORTH (NJ) (dpa-AFX) - The U.S. Food and Drug Administration has approved an expanded indication for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through

KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK) said it has presented positive results from the phase 1/2 study, dubbed as V116-001, evaluating the safety, tolerability and immunogenicity of

NEW YORK CITY (dpa-AFX) - On this day last year, i.e., June 8, 2021, the FDA approved Pfizer Inc.'s (PFE) Prevnar 20 vaccine to prevent pneumonia and invasive disease caused by 20 types of pneumococcal

BOULDER, Colo., May 10, 2022for rapid and accurate assessment of pneumococcal vaccines at all stages of manufacturing, including multivalent drug product. This launch is accompanied by the availability

KENILWORTH (NJ) (dpa-AFX) - Merck & Co. Inc. (MRK) said that its investigational 21-valent pneumococcal conjugate vaccine ,V116, has received Breakthrough Therapy Designation from the U.S. Food